A carregar...
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines
BACKGROUND: Despite recent advances in treatment strategies, it is still difficult to cure patients with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase inhibitor for systemic chemotherapy in patients with advanced HCC. The majority of advanced HCC patients are resista...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5360329/ https://ncbi.nlm.nih.gov/pubmed/28323861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0174153 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|